Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Amyloid removal has been used as a surrogate outcome in Alzheimer's disease trials, allowing accelerated approval of aducanumab and lecanemab. The A4 (Alzheimer's Clinical Trial Consortium A4/LEARN) trial's individual-level data supports novel methods to evaluate amyloid's validity as a surrogate for cognitive decline.
Methods: In 812 participants, cognitive and functional change was measured using the CDR-SB score. Instrumental-variable analysis estimated the effect of amyloid reduction; mediation analysis quantified solanezumab's cognitive effect mediated by amyloid reduction.
Results: Each 10 centiloid reduction due to randomization to treatment was associated with 0.026 higher CDR-SB (95% CI: -0.013, 0.065). 14.6% of solanezumab's effect on cognition was mediated by amyloid reduction (95% CI: -122%, 208%).
Discussion: Estimates showing near-zero effects of amyloid reduction on cognitive decline suggest minimal impact of amyloid reduction in populations with little disease progression. Replication in anti-amyloid trials with larger treatment effects could guide treatment and regulatory decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330451 | PMC |
| http://dx.doi.org/10.1101/2025.07.21.25331942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural and Functional Determinants of ARIA-H Risk in Anti-Amyloid Monoclonal Antibodies: A Comparative Mechanistic Framework for Alzheimer's Immunotherapy Development.
Curr Neuropharmacol
August 2025
Department of Neurology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
Introduction: Amyloid-beta-targeting monoclonal antibodies (mAbs) for Alzheimer's disease frequently induce amyloid-related imaging abnormalities with hemorrhage (ARIA-H), yet systematic comparisons of ARIA-H incidence across therapeutic agents remain limited. Post-approval research prioritizes dosing over mechanism, leaving unresolved whether ARIA-H variations originate from intrinsic mAb properties. We address two gaps: comparative ARIA-H risk stratification among clinically available/investigational mAbs, and elucidation of structural/functional features influencing ARIA-H susceptibility.
View Article and Find Full Text PDFRole of GSK-3 Inhibition in Alzheimer's Disease Therapy.
Curr Alzheimer Res
September 2025
Department of Biochemistry, General Medicine Practice Program, Batterjee Medical College, Jeddah, Saudi Arabia.
A serine/threonine kinase with a wide variety of substrates, Glycogen Synthase Kinase-3 (GSK-3) is widely expressed. GSK-3 is a key player in cell metabolism and signaling, modulating numerous cellular functions and playing significant roles in both healthy and diseased states. The two histopathological features of Alzheimer's disease, the intracellular neurofibrillary tangles composed of hyperphosphorylated tau, and the extracellular senile plaques composed of beta-amyloid, have been linked to GSK-3.
View Article and Find Full Text PDFBenefits of physical activity on cognitive function in patients with neurocognitive disorders: A systematic review.
J Frailty Aging
September 2025
Geriatrics Department, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, 75010 Paris, France; Paris-Cité University, Inserm U1144, Paris, France; Cognitive Neurology Center, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, 75010 Paris, France. Electronic address: matthi
Neurocognitive disorders, particularly in older adults, significantly affect functional abilities and global health. Physical activity has emerged as a potential non-pharmacological intervention to improve cognitive performance in patients with neurodegenerative diseases. This review specifically addressed the issue of tailored physical activity interventions for individuals with various neurocognitive disorders.
View Article and Find Full Text PDFExtracellular vesicle signature is associated with cardio-metabolic improvement after bariatric surgery.
Eur J Prev Cardiol
September 2025
Institute of Clinical Chemistry, University and University Hospital of Zurich, Zurich, Switzerland.
Aims: Bariatric surgery (BS) reduces obesity-associated systemic inflammation leading to multiple cardiovascular (CV) and metabolic benefits. Here, we tested whether measuring vaso-inflammatory cytokines, gut hormones, and circulating extracellular vesicles (EV) provide vaso-inflammatory-metabolic signatures that better correlate to CV-metabolic outcomes after BS, compared to a standard clinical assessment including body weight (BW) loss and traditional CV risk factors.
Methods: In 111 patients with severe obesity, conventional clinical-biochemical parameters and non-conventional vaso-inflammatory-metabolic markers were analyzed at baseline, after 1- (T12) and 3-years (T36) post-BS and were associated to post-surgical BW loss and improvement of patients' CV-metabolic profile.
Introduction: Donanemab is an immunoglobulin G1 antibody that targets an N-terminal truncated form of amyloid beta present in mature plaques. Treatment-emergent (TE) anti-drug antibodies (ADAs) were quantified in donanemab-treated participants from two pivotal clinical trials, and effects of TE ADAs on donanemab pharmacokinetics, efficacy, and safety were assessed.
Methods: Data were pooled from the phase 2 TRAILBLAZER-ALZ (NCT03367403) and phase 3 TRAILBLAZER-ALZ 2 trials (NCT04437511).